TY - JOUR AU - T. M. Solomenchuk AU - L. M. Kopchak AU - G. V. Tshngryan PY - 2018/12/05 Y2 - 2024/03/29 TI - Fatigue and quality of life in patients with arterial hypertention: effectiveness of meldonium JF - Likars'ka sprava JA - Lik. sprava VL - IS - 3-4 SE - Guide lines for the practitioner DO - 10.31640/3-4.2018(16) UR - https://liksprava.com/index.php/journal/article/view/200 AB - The aim of the study was to investigate the influence of meldonium (Trizipine® Long) on the health-related quality of life (HRQL) and fatigue in patients with arterial hypertension (AH). A total of 49 hypertensive outpatients with fatigue, 20 male (40.8 %) and 29 female (59.2 %) were examined. The study did not involve patients with concomitant diseases, symptom of which is fatigue. Participants were divided into 2 groups. Twenty-five patients (group 1) received antihypertensive treatment according to the guidelines of the European Society of Cardiology (ESC, 2013). Twenty-four patients (group 2) received antihypertensive treatment with the addition of 1000 mg of meldonium once a day for 8 weeks. The examination included routine clinical, laboratory, and instrumental investigations, including ambulatory blood pressure monitoring (ABPM). The Multidimensional Fatigue Inventory (MFI-20) questionnaire was used to assess the presence and severity of fatigue. The HRQL was assessed by 36-Item Short-Form Health Survey test (SF-36.) The results were evaluated at first appointment and after 8 weeks of treatment. Almost all the patients suffered from moderate fatigue in two subscales: General Fatigue and Physical Fatigue, according to MFI-20 test. In hypertensive patients suffering from fatigue, with poor blood pressure control, we found a significant decrease of HROL. It has been shown that the use of antihypertensive therapy with the addition of meldonium results in significant reduction in fatigue and improving of HRQL as well as improving of the ABPM main data. ER -